<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.2" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMABHR</journal-id>
<journal-title-group><journal-title>International Journal of Medical and All Body Health Research</journal-title><abbrev-journal-title>IJMABHR</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2582-8940</issn>
<publisher><publisher-name>Anfo Publication House</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">453</article-id>
<article-id pub-id-type="doi">10.54660/IJMBHR.2026.7.1.176-180</article-id>
<title-group><article-title>Reactivation of Hepatitis B in a Patient Coinfected with Hiv/Hbv Undergoing Therapy Without the use of Tenofovir: A Case Report</article-title></title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Senise</surname><given-names>Bruna Lourenço</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author"><name><surname>Bezerra</surname><given-names>Thiago Augusto Rochetti</given-names></name><xref ref-type="aff" rid="aff2"/></contrib>
<aff id="aff1"><label>1</label>Graduated, Emílio Ribas Institute of Infectious Diseases, Lusíadas University Center (UNILUS), Santos, São Paulo, Brazil</aff>
<aff id="aff2"><label>2</label>Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil</aff>
</contrib-group>
<pub-date publication-format="electronic" date-type="pub"><day>10</day><month>02</month><year>2026</year></pub-date>
<volume>7</volume>
<issue>1</issue>
<fpage>176</fpage>
<lpage>180</lpage>
<permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/?utm"><license-p>CC BY-NC-SA 4.0</license-p></license></permissions>
<self-uri xlink:href="https://www.allmedicaljournal.com/article/453/reactivation-of-hepatitis-b-in-a-patient-coinfected-with-hiv-hbv-undergoing-therapy-without-the-use"/>
<self-uri content-type="pdf" xlink:href="https://www.allmedicaljournal.com/article/453/download"/>
<abstract><p>Coinfection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is a significant clinical challenge, especially during changes in antiretroviral therapy. Tenofovir is a key drug for the simultaneous suppression of HIV and HBV, and its suspension can lead to HBV reactivation in individuals with latent or occult infection. This study reports a case of hepatitis B reactivation after tenofovir withdrawal. The patient was a 68-year-old male diagnosed with HIV in 1985, on antiretroviral therapy since 1998, and with an undetectable HIV viral load for several years. In February 2024, tenofovir disoproxil fumarate was discontinued due to renal changes and osteopenia. Three months after withdrawal, the patient presented with a significant elevation of liver transaminases. Initially, drug-induced hepatotoxicity was considered; however, investigation revealed HBsAg, total anti-HBc, and HBeAg reactants, in addition to an HBV viral load of 16,100,000 copies, confirming viral reactivation. The introduction of tenofovir alafenamide resulted in a progressive reduction in HBV viral load and laboratory improvement. The case highlights the need for complete serological evaluation for hepatitis B before changes in the antiretroviral regimen and the risk associated with inadvertent suspension of tenofovir in coinfected patients.</p></abstract>
<kwd-group kwd-group-type="author"><kwd>HIV</kwd><kwd>Hepatitis B</kwd><kwd>HIV/HBV coinfection</kwd><kwd>Viral reactivation</kwd><kwd>Tenofovir</kwd></kwd-group>
</article-meta>
</front>
<back><ref-list><title>References</title>
<ref id="R1"><label>1</label><mixed-citation>World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery, and monitoring. Geneva: World Health Organization; 2021.</mixed-citation></ref>
<ref id="R2"><label>2</label><mixed-citation>Brazil. Ministry of Health. Secretariat of Science, Technology, Innovation, and Health Complex. Secretariat of Health and Environmental Surveillance. Clinical protocol and therapeutic guidelines for hepatitis B and coinfections. 1st ed. Brasília: Ministry of Health; 2023.</mixed-citation></ref>
<ref id="R3"><label>3</label><mixed-citation>Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49(Suppl 5):S138– S145. doi:10.1002/hep.22883.</mixed-citation></ref>
<ref id="R4"><label>4</label><mixed-citation>Cheng Z, Lin P, Cheng N. HBV/HIV coinfection: impact on the development and clinical treatment of liver diseases. Front Med. 2021;8:713981. doi:10.3389/fmed.2021.713981.</mixed-citation></ref>
<ref id="R5"><label>5</label><mixed-citation>Fasano M, et al. Management of chronic hepatitis B in HIV-coinfected patients. Viruses. 2022;14(9):2022. doi:10.3390/v14092022.</mixed-citation></ref>
<ref id="R6"><label>6</label><mixed-citation>Gupta A, et al. Prevention and management of hepatitis B virus infection in adults with HIV. Baltimore: Johns Hopkins University; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK584516/</mixed-citation></ref>
<ref id="R7"><label>7</label><mixed-citation>Malagnino V, et al. Role of HBcAb positivity in increase of HIV-RNA detectability after switching to a two-drug regimen lamivudine-based treatment. Viruses. 2023;15(1):193. doi:10.3390/v15010193.</mixed-citation></ref>
<ref id="R8"><label>8</label><mixed-citation>Salpini R, et al. Kinetics of hepatitis B virus replication in anti-HBc positive people with HIV switching to tenofovir-sparing therapy. Int J Infect Dis. 2025;150:107294. doi:10.1016/j.ijid.2024.107294.</mixed-citation></ref>
<ref id="R9"><label>9</label><mixed-citation>Mican R, et al. Hepatitis B reactivation after tenofovir withdrawal in an HIV-infected patient. AIDS. 2021;35(10):1707–1708. doi:10.1097/QAD.0000000000002941.</mixed-citation></ref>
<ref id="R10"><label>10</label><mixed-citation>Toka B, et al. Comparison of tenofovir disoproxil fumarate and entecavir in the prophylaxis of HBV reactivation. Dig Dis Sci. 2021;66(7):2417–2426. doi:10.1007/s10620-020-06506-w.</mixed-citation></ref>
<ref id="R11"><label>11</label><mixed-citation>Corcorran MA, Kim HN. Chronic hepatitis B and HIV coinfection. Top Antivir Med. 2023;31(1):14–22.</mixed-citation></ref>
<ref id="R12"><label>12</label><mixed-citation>Brazil. Ministry of Health. Secretariat of Science, Technology, Innovation, and Health Complex. Secretariat of Health Surveillance and Environment. Clinical protocol and therapeutic guidelines for the management of HIV infection in adults: Module 2 – Coinfections and opportunistic infections. Brasília: Ministry of Health; 2024.</mixed-citation></ref>
<ref id="R13"><label>13</label><mixed-citation>Singh KP, et al. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31(15):2035–2052. doi:10.1097/QAD.0000000000001574.</mixed-citation></ref>
<ref id="R14"><label>14</label><mixed-citation>Moretto F, et al. Isolated anti-HBc: significance and management. J Clin Med. 2020;9(1):202. doi:10.3390/jcm9010202.</mixed-citation></ref>
<ref id="R15"><label>15</label><mixed-citation>Weissmann L. Plasma detection of viral DNA in individuals with chronic hepatitis B virus infection coinfected with HIV [thesis]. São Paulo: University of São Paulo; 2020.</mixed-citation></ref>
<ref id="R16"><label>16</label><mixed-citation>Souza DAC, et al. Characterization of HIV and hepatitis B coinfection in the population of a referral hospital in São Luís-MA. São Luís; 2023.</mixed-citation></ref>
<ref id="R17"><label>17</label><mixed-citation>Abdullahi A, et al. Hepatitis B virus infection and reactivation during nucleos(t)ide reverse transcriptase inhibitor-sparing antiretroviral therapy in a high-HBV endemicity setting. Open Forum Infect Dis. 2018;5(10):ofy251. doi:10.1093/ofid/ofy251.</mixed-citation></ref>
<ref id="R18"><label>18</label><mixed-citation>Mohareb AM, et al. Virological and serological outcomes in people with HIV-HBV coinfection who discontinued tenofovir therapy. J Virus Erad. International Journal of Medical and All Body Health Research www.allmedicaljournal.com 2024;10(4):100574. doi:10.1016/j.jve.2024.100574.</mixed-citation></ref>
<ref id="R19"><label>19</label><mixed-citation>Salpini R, et al. Cryptic HBV replicative activity revealed in anti-HBc-positive/HBsAg-negative patients with HIV. Microorganisms. 2020;8(11):1819. doi:10.3390/microorganisms8111819.</mixed-citation></ref>
<ref id="R20"><label>20</label><mixed-citation>Myint A, Tong MJ, Beaven SW. Reactivation of hepatitis B virus: a review of clinical guidelines. Clin Liver Dis. 2020;15(4):162–167.</mixed-citation></ref>
<ref id="R21"><label>21</label><mixed-citation>Brazil. Ministry of Health. Department of HIV/AIDS, Tuberculosis, Viral Hepatitis, and STIs. Secretariat of Health Surveillance and Environment. Epidemiological Bulletin on Viral Hepatitis. Special issue. Brasília: Ministry of Health; 2025.</mixed-citation></ref>
<ref id="R22"><label>22</label><mixed-citation>Mohareb AM, et al. Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B. Lancet HIV. 2022;9(8):e585–e594.</mixed-citation></ref>
<ref id="R23"><label>23</label><mixed-citation>Begré L, et al. Circulating HBV RNA and hepatitis B core–related antigen trajectories in persons with HIV/HBV coinfection and hepatitis B surface antigen loss during tenofovir therapy. J Infect Dis. 2024;230(4):e954–e963. doi:10.1093/infdis/jiae189.</mixed-citation></ref>
<ref id="R24"><label>24</label><mixed-citation>Corcorran MA, Kim HN. Strategies for hepatitis B virus prevention in people living with HIV. Curr HIV/AIDS Rep. 2023;20(6):451–457. doi:10.1007/s11904-023-00658-9.</mixed-citation></ref>
<ref id="R25"><label>25</label><mixed-citation>Uzun T. Prolonged cholestatic hepatitis B as the initial presentation of HIV coinfection: a case report. Hepat Mon. 2025;25(1):e165783. doi:10.5812/hepatmon-165783.</mixed-citation></ref>
<ref id="R26"><label>26</label><mixed-citation>Coffin CS, et al. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus/human immunodeficiency virus co-infected patients. J Clin Virol. 2013;57(2):103–108. doi:10.1016/j.jcv.2013.01.016.</mixed-citation></ref>
<ref id="R27"><label>27</label><mixed-citation>Chen S, et al. HBsAg loss in HIV/HBV coinfected patients: hepatitis B cure insights and implications. Infect Dis Immun. 2025;5(4):249 –259. doi:10.1097/ID9.0000000000000174.</mixed-citation></ref>
<ref id="R28"><label>28</label><mixed-citation>Hawkins C, et al. Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy. AIDS. 2022;36(7):975–984. doi:10.1097/QAD.0000000000003193.</mixed-citation></ref>
<ref id="R29"><label>29</label><mixed-citation>Ma H, et al. Overview of the immunological mechanisms in hepatitis B virus reactivation: implications for disease progression and management strategies. World J Gastroenterol. 2024;30(10):1295. doi:10.3748/wjg.v30.i10.1295.</mixed-citation></ref>
<ref id="R30"><label>30</label><mixed-citation>Dossaji Z, et al. A review of hepatitis B reactivation risk on immunosuppressants with a focus on newer immunomodulators. Curr Hepatol Rep. 2024;23(2):253– 267. doi:10.1007/s11901-024-00662-7.</mixed-citation></ref>
<ref id="R31"><label>31</label><mixed-citation>Bittencourt JASS, et al. Contribution to the study of chronic liver disease in HIV-infected patients. Rio de Janeiro: Rio de Janeiro State University; 2021. Available from: http://www.bdtd.uerj.br/handle/1/22232</mixed-citation></ref>
</ref-list></back>
</article>